Under construction – not a live service
Sign in
Taking people in GermanyPhase 1

Tests modified immune cells against ROR1 positive cancers in early human study

Tests modified immune cells in adults with ROR1-positive cancers, including leukemia and lymphoma.

Key facts

Who runs it
Universitaetsklinikum Wuerzburg AöR
Where
Berlin, Cologne, and Wuerzburg, GermanySee the 3 sites
Registry title
A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors
Status
Recruiting
Phase
Phase 1
People taking part
44 people, planned
Started
9 Apr 2025
Expected to end
1 Nov 2042
Type of study
Interventional
Record updated
13 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a ROR1 positive tumor, such as adrenocortical, breast, ovarian cancer, chronic lymphocytic leukemia or mantle cell lymphoma.

Age
18 years or older
Sex
Women and men can join.
Biomarker or test result
The tumor must be ROR1 positive.

Where in Germany

  • Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
  • Universitaetsklinikum Koeln AöRCologne, GermanyTaking people
  • Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests modified immune cells against ROR1 positive cancers in early human studyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 April 2026